![\"\"](\"https:\/\/www.rightsdirect.com\/wp-content\/uploads\/sites\/6\/2023\/05\/jane-reed-685x1024-1.jpg\")
<\/figure>\n<\/div>\n\n\nWenn Sie den Velocity of Content Blog des CCC<\/a> seit seiner Gr\u00fcndung verfolgen, sind Sie wahrscheinlich auf einen Blogbeitrag (oder mehrere) von Jane Reed<\/a> gesto\u00dfen, der Leiterin der Life-Science-Strategie von Linguamatics.\u00a0<\/h3>\n\n\n\nNun haben unsere Kolleg:innen vom CCC mit Jane Reed dar\u00fcber gesprochen, wie sich Linguamatics entwickelt hat, wie das Unternehmen die sich st\u00e4ndig \u00e4ndernden Bed\u00fcrfnisse seiner Kund:innen erf\u00fcllt, und welche gr\u00f6\u00dften Branchenumw\u00e4lzungen sie in den vergangenen zehn Jahren erlebt hat.\u00a0<\/h3>\n\n\n\n
<\/p>\n\n\n\n
Tell us an interesting fact about Linguamatics that people may not know. <\/h4>\n\n\n\n
JR: Did you know that one of Linguamatics\u2019 founders met Queen Elizabeth? <\/p>\n\n\n\n
Linguamatics received the Queen\u2019s Award for Enterprise in 2014<\/a>, an award for International Trade in recognition of outstanding growth in export sales across USA and Europe for its Natural Language Processing [NLP] text analytics software platform. As part of the award, Phil Hastings our Senior Director of Business Development and David Milward, one of the founders and previous CTO went to Buckingham Palace to receive the award from the late HM Queen Elizabeth.\u00a0\u00a0\u00a0<\/p>\n\n\n\nLinguamatics has been serving the healthcare and pharma space for many years. In a recent blog post you talk about the \u201chealthcare data revolution.\u201d Can you give us a brief explainer of what\u2019s happening in the industry \u2013 and how Linguamatics is responding? <\/h4>\n\n\n\n
JR: The last few years have witnessed the ongoing expansion of real-world healthcare data (RWD) sources, which has been accompanied by a rise in the recognition and approval of these data by global regulatory agencies, including the U.S. Food and Drug Administration, the European Medicines Agency, and many health technology assessment agencies. The use of real-world evidence (RWE) to support regulatory decision making, such as the approval of new indications for approved drugs, has been given added emphasis by the 21st Century Cures Act (2016). <\/p>\n\n\n\n
Increasingly, rich RWD sources are being used with cutting-edge analytical technologies to deliver previously unattainable insights. These new data sources and tools hold out the possibility of improving drug discovery and development processes end-to-end, addressing unmet medical needs, reducing healthcare costs, and enhancing the quality of care. Many sources of real-world data contain large amounts of unstructured text (e.g. medical records, literature, congress reports, or even social media for patient-reported outcomes). IQVIA NLP from Linguamatics extracts the key facts, using relevant ontologies and focused queries, transforming real world data into actionable intelligence for decision making. <\/p>\n\n\n\n
How are we responding? <\/h4>\n\n\n\n
As the understanding of the value of RWD grows, we are seeing the need to cater for a wider ecosystem of users, including expert informaticians, data scientists, or business users such as scientists and clinicians. To provide value, we have developed a broad suite of offerings<\/a> to enable all these users to gain the value we know NLP can bring from unstructured text relevant for RWD and RWE. We are working with partners \u2013 both within IQVIA and outside \u2013 to provide comprehensive solutions that customers need, integrated with our NLP. Linguamatics doesn\u2019t need to do it all, but we do need to know who to work with, for best practice and best customer value, and we do. <\/p>\n\n\n\nThe Linguamatics I2E application delivers text mining capabilities across a broad range of application areas. Tell us a little about how I2E works. <\/p>\n\n\n\n
JR: Linguamatics I2E has been our mainstay NLP product for over 20 years; more recently we have released new products such as NLP Data Factory and Human Assisted Review Tool, ideal for data scientists, expert informaticians, end-user scientists and researchers. All these products share the NLP Core Platform to tackle any sort of unstructured text and transform into structured, enriched, information. I2E itself is a powerful search tool that enables the creation of sophisticated queries than combine word, phrases, ML-predicted entities, terminologies, linguistic units, regular expressions and much more \u2013 linked together with relations that extend Boolean logic (AND, OR, NOT, etc). As well as search, I2E enables the user to \u201cshape\u201d their results with appropriate features extracted from source documents, and then export them to a variety of commonly-used output formats, e.g. XML, JSON, TSV, HTML, Docx, etc. Under-the-hood, the NLP Core platform is performing high-throughput processing of incoming documents which understands the fundamental elements that make up text \u2013 sentences, phrases, nouns and verbs, other parts of speech, morphology of words, and more. Our NLP also leverages a range of ontologies \u2013 all the key concepts in life science and healthcare, such as drugs, genes, diseases, with millions of terms and synonyms to enable effective search. It also recognizes chemical names, patterns of words in text and assign them as dates, dosages, mutations, measurements, etc. And if that is not enough, NLP Core exposes an API to give customers even more fine-grained control over the NLP! <\/p>\n\n\n\n
Natural language processing is undoubtedly useful for data scientists and teams heavily invested in R&D outcomes. What are some areas of a business where NLP can play a big role, but is often underutilized? <\/h4>\n\n\n\n
Linguamatics has been serving the healthcare and pharma space for many years. In a recent blog post you talk about the \u201chealthcare data revolution.\u201d Can you give us a brief explainer of what\u2019s happening in the industry \u2013 and how Linguamatics is responding? <\/h4>\n\n\n\n
JR: The last few years have witnessed the ongoing expansion of real-world healthcare data (RWD) sources, which has been accompanied by a rise in the recognition and approval of these data by global regulatory agencies, including the U.S. Food and Drug Administration, the European Medicines Agency, and many health technology assessment agencies. The use of real-world evidence (RWE) to support regulatory decision making, such as the approval of new indications for approved drugs, has been given added emphasis by the 21st Century Cures Act (2016). <\/p>\n\n\n\n
Increasingly, rich RWD sources are being used with cutting-edge analytical technologies to deliver previously unattainable insights. These new data sources and tools hold out the possibility of improving drug discovery and development processes end-to-end, addressing unmet medical needs, reducing healthcare costs, and enhancing the quality of care. Many sources of real-world data contain large amounts of unstructured text (e.g. medical records, literature, congress reports, or even social media for patient-reported outcomes). IQVIA NLP from Linguamatics extracts the key facts, using relevant ontologies and focused queries, transforming real world data into actionable intelligence for decision making. <\/p>\n\n\n\n
How are we responding? <\/h4>\n\n\n\n
As the understanding of the value of RWD grows, we are seeing the need to cater for a wider ecosystem of users, including expert informaticians, data scientists, or business users such as scientists and clinicians. To provide value, we have developed a broad suite of offerings<\/a> to enable all these users to gain the value we know NLP can bring from unstructured text relevant for RWD and RWE. We are working with partners \u2013 both within IQVIA and outside \u2013 to provide comprehensive solutions that customers need, integrated with our NLP. Linguamatics doesn\u2019t need to do it all, but we do need to know who to work with, for best practice and best customer value, and we do. <\/p>\n\n\n\n The Linguamatics I2E application delivers text mining capabilities across a broad range of application areas. Tell us a little about how I2E works. <\/p>\n\n\n\n JR: Linguamatics I2E has been our mainstay NLP product for over 20 years; more recently we have released new products such as NLP Data Factory and Human Assisted Review Tool, ideal for data scientists, expert informaticians, end-user scientists and researchers. All these products share the NLP Core Platform to tackle any sort of unstructured text and transform into structured, enriched, information. I2E itself is a powerful search tool that enables the creation of sophisticated queries than combine word, phrases, ML-predicted entities, terminologies, linguistic units, regular expressions and much more \u2013 linked together with relations that extend Boolean logic (AND, OR, NOT, etc). As well as search, I2E enables the user to \u201cshape\u201d their results with appropriate features extracted from source documents, and then export them to a variety of commonly-used output formats, e.g. XML, JSON, TSV, HTML, Docx, etc. Under-the-hood, the NLP Core platform is performing high-throughput processing of incoming documents which understands the fundamental elements that make up text \u2013 sentences, phrases, nouns and verbs, other parts of speech, morphology of words, and more. Our NLP also leverages a range of ontologies \u2013 all the key concepts in life science and healthcare, such as drugs, genes, diseases, with millions of terms and synonyms to enable effective search. It also recognizes chemical names, patterns of words in text and assign them as dates, dosages, mutations, measurements, etc. And if that is not enough, NLP Core exposes an API to give customers even more fine-grained control over the NLP! <\/p>\n\n\n\nNatural language processing is undoubtedly useful for data scientists and teams heavily invested in R&D outcomes. What are some areas of a business where NLP can play a big role, but is often underutilized? <\/h4>\n\n\n\n